Vertex Pharmaceuticals Q4 2024 Earnings Exceed Revenue Expectations
Vertex Pharmaceuticals (VRTX) beat Q4 2024 revenue estimates with $2.91B, a 15.7% YoY increase. While EPS slightly missed expectations, the company’s FY2025 revenue guidance aligns with analyst projections.
Vertex Pharmaceuticals Q4 2024 Earnings Exceed Revenue Expectations Read More »